International Assets Investment Management LLC Has $713,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

International Assets Investment Management LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 736 shares of the biopharmaceutical company’s stock after acquiring an additional 63 shares during the period. International Assets Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $713,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of REGN. Norges Bank bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $932,571,000. First Trust Advisors LP lifted its holdings in Regeneron Pharmaceuticals by 115.2% during the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after purchasing an additional 195,902 shares during the last quarter. abrdn plc lifted its holdings in Regeneron Pharmaceuticals by 552.8% during the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock worth $193,136,000 after purchasing an additional 186,215 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Regeneron Pharmaceuticals by 129.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock valued at $190,170,000 after purchasing an additional 122,103 shares during the period. Finally, National Bank of Canada FI increased its position in Regeneron Pharmaceuticals by 161.8% during the 4th quarter. National Bank of Canada FI now owns 116,227 shares of the biopharmaceutical company’s stock worth $105,185,000 after buying an additional 71,838 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $1,053.14 on Monday. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $116.05 billion, a PE ratio of 31.11, a P/E/G ratio of 2.16 and a beta of 0.13. The firm has a fifty day simple moving average of $967.84 and a 200 day simple moving average of $944.29. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $1,059.80.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Royal Bank of Canada upped their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $998.09.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 787 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the transaction, the chief executive officer now owns 64,198 shares in the company, valued at approximately $65,162,253.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 787 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the sale, the chief executive officer now owns 64,198 shares of the company’s stock, valued at approximately $65,162,253.96. The disclosure for this sale can be found here. Insiders sold a total of 61,215 shares of company stock valued at $60,414,782 in the last quarter. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.